Case Report Details Body Composition and Hormone Shifts from LGD-4033 and MK-677 Use
Background
Selective Androgen Receptor Modulators (SARMs) like LGD-4033 and Growth Hormone (GH) secretagogues such as MK-677 are increasingly used off-label for their purported anabolic effects and improvements in body composition. While animal studies and limited human trials exist for individual compounds, the combined physiological impact of these agents, particularly on circulating biomarkers and skeletal muscle androgen receptor content, remains poorly understood. This case report aims to provide detailed insights into the specific changes observed in a human subject using both LGD-4033 and MK-677 simultaneously.
Results
After 8 weeks of combined LGD-4033 and MK-677 use, the subject demonstrated significant changes in body composition and endocrine markers. Body composition analysis revealed a 2.8 kg increase in lean body mass and a 1.5 kg decrease in fat mass, resulting in a 2.5% reduction in body fat percentage. Circulating total testosterone levels were profoundly suppressed, showing a 78% decrease from 550 ng/dL at baseline to 120 ng/dL post-intervention, while IGF-1 (Insulin-like Growth Factor 1) levels increased by 45%. Skeletal muscle biopsies indicated a 30% upregulation in androgen receptor content within the muscle tissue. Liver enzyme markers (ALT, AST) showed a transient, mild elevation but remained within clinically acceptable ranges. > The most striking finding was the significant increase in lean body mass coupled with a marked suppression of endogenous testosterone, suggesting potent anabolic activity alongside a clear impact on the hypothalamic-pituitary-gonadal axis.
Why It Matters
This case report provides crucial, albeit preliminary, human data on the combined effects of LGD-4033 and MK-677, highlighting their potent impact on body composition and endocrine function. The observed anabolic effects (increased lean mass, decreased fat mass) are consistent with the purported benefits of these compounds, but the significant testosterone suppression underscores potential risks. This study emphasizes the importance of understanding the physiological consequences of such combinations, especially given their widespread off-label use. Further controlled clinical trials are urgently needed to fully characterize the safety profile and long-term efficacy of these compounds in humans, potentially informing future therapeutic applications or regulatory guidelines.